300676.SZ
华大基因
SZSE · Healthcare · M 科研服务 · CN
CNY 41.90
−0.71%Year over year
Reported trailing growth
- Revenue
- +3.4%
- EBITDA
- —
- EBIT
- +44.1%
- EPS
- +41.3%
- Free cash flow
- +56.4%
- Operating cash flow
- +167.7%
Forward estimates
Based on analyst estimates
- Revenue
- -75.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -19.3%
- EBITDA
- +84.5%
- EBIT
- +32.2%
- Net income
- +31.7%
- EPS
- +32.3%
- Free cash flow
- -31.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026